{"id":3607,"date":"2026-05-11T17:00:00","date_gmt":"2026-05-11T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=367c6b7b2dab6d09a6048f68a019ee3a"},"modified":"2026-05-11T17:00:00","modified_gmt":"2026-05-11T15:00:00","slug":"forge-biologics-announces-seven-presentations-at-the-american-society-of-gene-and-cell-therapy-asgct-29th-annual-meeting","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=3607","title":{"rendered":"Forge Biologics Announces Seven Presentations at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\n<i>Oral and poster presentations highlight data from Forge\u2019s FUEL\u2122 AAV manufacturing platform and advancements in process characterization and late-phase manufacturing to support the growing number of gene therapy programs advancing toward commercialization<\/i><\/li>\n<\/ul><p>COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, (\u201cForge\u201d), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver seven presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29<sup>th<\/sup> Annual Meeting, taking place May 11-15, 2026, in Boston. The presentations include two technical sessions, co-chairing an oral abstract session, and four scientific posters.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260511364284\/en\/2800715\/5\/Forge_Aji_Text_Primary_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260511364284\/en\/2800715\/22\/Forge_Aji_Text_Primary_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260511364284\/en\/2800715\/5\/Forge_Aji_Text_Primary_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260511364284\/en\/2800715\/21\/Forge_Aji_Text_Primary_Logo.jpg\" \/><\/a><p>\n\u201cAs the gene therapy field enters a critical phase of maturation, manufacturing must evolve to support both larger patient populations and the growing number of programs advancing into late-stage development,\u201d said John Maslowski, President and Chief Executive Officer of Forge. \u201cAt ASGCT, we\u2019re proud to showcase how our FUEL\u2122 platform is enabling more doses per batch, improving scalability for broader indications. We\u2019ll also highlight our continued investments in process characterization and late-phase manufacturing to help developers move efficiently from clinical development to commercialization.\u201d<\/p><p>\n<b>SESSION PRESENTATIONS<\/b><\/p><p>\n<b>Sponsored Symposia\n<br\/><\/b><b>Title:<\/b> More Doses, Same Run: Process Innovation and Late-Phase Manufacturing Frameworks for Developers\n<br\/><b>Presenters:\n<br\/><\/b>Frank Agbogbo, Ph.D., Vice President of Process Development, Forge\n<br\/>Adam Davis, Ph.D., Vice President of Analytical Development, Forge\n<br\/>John Kerwin, Ph.D., Senior Vice President of Operations, Ascidian Therapeutics\n<br\/>Brianna Barrett, Ph.D., Director of Technical Sales &amp; Scientific Advisory, Forge (moderator)\n<br\/><b>Date and Time:<\/b> Wednesday, May 13, 10:15-10:45 a.m.\n<br\/><b>Location: <\/b>Room 109AB<\/p><p>\n<b>Tools &amp; Technology Forum\n<br\/><\/b><b>Title:<\/b> Validation of AUC Assay to Characterize AAV Empty to Full Capsid Ratio\n<br\/><b>Presenter:<\/b> Micah Witte, Senior Scientist, Analytical Development\n<br\/><b>Date and Time:<\/b> Tuesday, May 12, 3:30-3:45 p.m.\n<br\/><b>Location:<\/b> Exhibit Hall Presentation Theater<\/p><p>\n<b>Session: <\/b>Oral Abstract Session\n<br\/><b>Title:<\/b> AAV Cell Line Development and Engineering\n<br\/><b>Co-Chair:<\/b> Frank Agbogbo, Ph.D., Vice President of Process Development\n<br\/><b>Date and Time:<\/b> Wednesday, May 13, 8:00-9:45 a.m.\n<br\/><b>Location: <\/b>MCEC Room 258ABC (Level 2)<\/p><p>\n<b>POSTER PRESENTATIONS<\/b><\/p><p>\n<b>Title: <\/b>The Role of a Drug Master File in Multi-Program Data Sharing and Improving Review Efficiency\n<br\/><b>Presenter:<\/b> Julianne Bartz, Senior Manager of Regulatory Affairs\n<br\/><b>Date and Time: <\/b>Tuesday,<b> <\/b>May 12, 5:00-6:30 p.m.\n<br\/><b>Poster # 1233<\/b><\/p><p>\n<b>Title: <\/b>Advancing Purification Technologies and Process Innovations to Support High rAAV Upstream Productivity and Meet Growing Industry Demand\n<br\/><b>Presenter:<\/b> Ganesh Krishnamoorthy, Director of Downstream Process Development\n<br\/><b>Date and Time: <\/b>Tuesday,<b> <\/b>May 12, 5:00-6:30 p.m.\n<br\/><b>Poster # 1164<\/b><\/p><p>\n<b>Title: <\/b>From Development to Commercialization: Late-Stage Process Characterization for rAAV Manufacturing\n<br\/><b>Presenter:<\/b> Keerthana Subramanian, Associate Director of Downstream Process Development\n<br\/><b>Date and Time: <\/b>Wednesday,<b> <\/b>May 13, 5:00-6:30 p.m.\n<br\/><b>Poster # 2164<\/b><\/p><p>\n<b>Title: <\/b>Advancing High-Yield Suspension HEK293 rAAV Manufacturing in Single-Use Bioreactors\n<br\/><b>Presenter:<\/b> Steven Wesel, Director of Upstream Process Development\n<br\/><b>Date and Time: <\/b>Thursday,<b> <\/b>May 14, 5:00-6:30 p.m.\n<br\/><b>Poster # 3145<\/b><\/p><p>\nFull abstracts are available on the <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fannualmeeting.asgct.org%2F&amp;esheet=54533179&amp;newsitemid=20260511364284&amp;lan=en-US&amp;anchor=ASGCT+Annual+Meeting+website&amp;index=1&amp;md5=957aaba5b1673739b4d32b86d3ca05dc\" rel=\"nofollow\" shape=\"rect\">ASGCT Annual Meeting website<\/a>, and conference participants can also access posters through the ASGCT website.<\/p><p>\nForge Biologics will be at booth #1349 in the Exhibitor Hall.<\/p><p>\n<b>About Forge Biologics<\/b><\/p><p>\nForge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge\u2019s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge\u2019s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.forgebiologics.com%2F&amp;esheet=54533179&amp;newsitemid=20260511364284&amp;lan=en-US&amp;anchor=www.forgebiologics.com&amp;index=2&amp;md5=62774b2b094b2915ca747df69e2bd76d\" rel=\"nofollow\" shape=\"rect\">www.forgebiologics.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Inquiries\n<br\/><\/b>Marina Corleto\n<br\/>Associate Director, Marketing &amp; Communications\n<br\/><a  href=\"mailto:media@forgebiologics.com\" rel=\"nofollow\" shape=\"rect\">media@forgebiologics.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Oral and poster presentations highlight data from Forge\u2019s FUEL\u2122 AAV manufacturing platform and advancements in process characterization and late-phase manufacturing to support the growing number of gene therapy programs advancing toward commercializa&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3607","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3607"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3607\/revisions"}],"predecessor-version":[{"id":3608,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3607\/revisions\/3608"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}